Core Points - The company announced an adjustment to the conversion price of its convertible bonds "Hao Yuan Convertible Bonds" due to the completion of share repurchase and cancellation related to performance commitments [1][3] - The previous conversion price was 40.58 CNY/share, and the new conversion price is adjusted to 40.59 CNY/share, effective from July 8, 2025 [2][5] - The company issued 822,350 lots (8,223,500 bonds) of convertible bonds totaling 82,235 million CNY, with a maturity of 6 years and an initial conversion price of 40.73 CNY/share [2][3] Adjustment Basis - The adjustment of the conversion price is based on the completion of the repurchase and cancellation of 47,725 shares at a total price of 1.00 CNY, as approved in board meetings and the annual shareholders' meeting [3][4] - The company followed the regulations set by the China Securities Regulatory Commission regarding the issuance of convertible bonds and the related adjustments to protect the rights of bondholders [3][5] Adjustment Methodology - The adjustment formula used for the conversion price is P1 = (P0 + A × k) / (1 + k), where P0 is the previous conversion price, A is the new share price, and k is the rate of share repurchase [5] - The calculation resulted in the new conversion price of approximately 40.59 CNY/share after the repurchase and cancellation of shares [5][6]
皓元医药: 上海皓元医药股份有限公司关于调整可转换公司债券“皓元转债”转股价格暨转股停复牌的公告